The FDA granted Breakthrough Device designation to the Novilase Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women seeking a breast conserving procedure.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe